Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Howard A. Burris, Margaret K. Callahan, Anthony W. Tolcher, Shivaani Kummar, Gerald Steven Falchook, Russell Kent Pachynski, Scott S. Tykodi, Geoffrey Thomas Gibney, Tanguy Y. Seiwert, Justin F. Gainor, Patricia LoRusso, James Hilbert, Josh F Apgar, Fei Hua, John M Burke, Manny Lazaro, Myles Clancy, Baoyu Ding, Elizabeth G. Trehu, Timothy Anthony Yap
Institutions: Sarah Cannon, Memorial Sloan Kettering Cancer Center, South Texas Accelerated Research Therapeutics, Stanford Medicine, Stanford University, HealthONE, Washington University in St. Louis, University of Washington, Fred Hutch Cancer Center, Moffitt Cancer Center, University of Chicago, Massachusetts General Hospital, Yale Cancer Center, Yale University, Applied BioMath (United States), Jounce Therapeutics (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891447266